Eder et al. Women with PsA have worse outcomes with advanced therapies. OR favours men for ACR 20, IL-17i (OR 1.76), IL-23i (OR 1.46), IL-12/23i (OR 2.66) and TNFi (OR 1.67). Maybe not JAKi (OR 1.09). Placebo OR 1.04. Abstr#1687 #ACR23 @RheumNow https://t.co/bkDmmmYECF https://t.co/VBLnJzhcaY

Evidence of window of opportunity concept in PsA. Certainly >52 weeks delay associates with worse outcomes. <12 weeks and 12-52 weeks similar. Abstr#1641 #ACR23 @RheumNow https://t.co/fMb3D9zl8B https://t.co/rHu29Eflo0

Window of opportunity in PsA Higher time to diagnosis in -female -higher enthesitis -less swollen joints -lower CRP If diag > 52 wks, over 3 yrs Less MDA, less remission Worse HAS-DI, PSAID Same Rx progression No diff between <12 wk & 12-52 wk @RheumNow #ACR23 ABST1641 https://t.co/Ek1CDFwENg

Haberman et al. In PsA non-white patients have higher tender (but not swollen) joint counts, higher radiographic axial disease, worse skin disease. Women have higher RAPID-3 scores. Abstr#1639 #ACR23 @RheumNow https://t.co/4SL7FLzNuE https://t.co/sVwk1VaSLS

#ACR23 Abs #1641 found early referral & dx in PsA associated w/ better clinical outcomes. MDA & DAPSA remission over 3 years less likely after > 52 weeks from symptom onset to dx. Likely delays in females w/ less swollen joints & lower CRP/ ESR https://t.co/meVQ1UisKY @rheumnow https://t.co/EBN7wJfjzK

Izokibep, IL-17Ai, #ACR23 abs #1688 demonstrated ACR70 in 52%, PASI100 in 71% and enthesitis complete resolution in 89% at week 46. Well tolerated, no dose-related AEs, similar safety with other IL-17Ai https://t.co/TQAIVa9H2j @rheumnow https://t.co/ihzxnuAsWw

MOSAIC study: #ACR23 Abs #1690 finds APR reduces clinical and objective MRI indices in PsA, confirming an effect of APR on clinical and inflammatory manifestations of PsA. https://t.co/F5D81FF1tj @rheumnow https://t.co/rGglgiOyDg

Apremilast associated with improvement in LDL, obesity and diabetic A1c in PsA pts, especially in those with worse levels at baseline! Can consider apremilast use in PsA with high burden of comorbid cardiometabolic diseases @RheumNow #ACR23 Abs#1414 https://t.co/fL9UWcaZgG